ISMPP is proud to announce that an article on its journey of engagement with patients as partners in medical publications was published on September 9, 2025 in Current Medical Research and Opinion (CMRO).

Artificial Intelligence (AI) is rapidly transforming the way we approach medical communications, but how are ISMPP members really using AI today? Where is AI helping the most, what barriers remain, and what do members want to learn next? These are the questions at the heart of our new GenAI in Practice: An ISMPP Member Survey on Awareness and Application, brought to you by the ISMPP AI Task Force.

The spirit of collaboration among the ISMPP community was alive and thriving at the 21st Annual Meeting of ISMPP, May 12-14, 2025, in Washington, DC.

The Request for Information (RFI) and Request for Proposal (RFP) processes are critical components of medical publication management, enabling stakeholders to evaluate services and establish strategic partnerships. The ISMPP ORION Task Force was established to assess current RFI/RFP practices, identify pain points, explore the benefits and drawbacks of standardization, and develop resources to enhance efficiency, quality, and transparency across stakeholders.

Predatory journals and congresses represent a significant and growing threat to the integrity of medical research, publishing, and scientific dissemination. Raising awareness across all scientific and medical communities, not just among those in publishing, is therefore crucial. This article provides practical guidance, particularly on how to identify and avoid predatory journals and congresses.

Healthcare information has never been more readily available than it is now. However, accessibility goes beyond mere access to information; it encompasses ensuring that all individuals—regardless of physical, sensory, or cognitive ability—can access, understand, and benefit from healthcare content. This article discusses the benefits of accessible healthcare content, current accessibility standards, common barriers, and practical tools and strategies to enhance accessibility.

You are a medical publication professional in a pharmaceutical company, working on a clinical trial publication for a novel drug that has the potential to revolutionize the treatment of a life-threatening disease. Some of the authors are keen to emphasize the promising efficacy outcomes without, in your opinion, incorporating the same level of detail about certain adverse events. What Would You Do?